The retinoblastoma protein (pRB) has the dual capability to negatively regulate both E2F-induced cell cycle entry and E2F1-induced apoptosis. In this report, we characterize a unique pRB-E2F1 interaction. Using mutagenesis to disrupt E2F1 binding, we find that the ability of pRB to regulate E2F1-induced apoptosis is diminished when this interaction is lost. Strikingly, this mutant form of pRB retains the ability to control E2F responsive cell cycle genes and blocks cell proliferation. These functional properties are the reciprocal of a previously described E2F binding mutant of pRB that interacts with E2F1, but lacks the ability to interact with other E2Fs. Our work shows that these distinct interactions allow pRB to separately regulate E2F-induced cell proliferation and apoptosis. This suggests a novel form of regulation whereby separate types of binding contacts between the same types of molecules can confer distinct functional outcomes.
Introduction
The E2F family of transcription factors are growthregulating molecules that are controlled by the retinoblastoma family of proteins. E2Fs function by regulating genes required for progression through the cell cycle (Trimarchi and Lees, 2002) . RB-E2F complexes are abundant when cells are in a quiescent state, while free E2Fs predominate in actively proliferating cells (Dyson, 1998) . In addition to regulating proliferation, retinoblastoma protein (pRB)-E2F1 interactions negatively regulate apoptosis indicating that these same molecules control distinct cellular processes (Johnson and Degregori, 2006) . In mammals, E2Fs 1-4 physically associate with pRB (Dyson, 1998) . E2Fs 1-3 encompass the activator class of E2Fs that are capable of promoting entry into S-phase and these E2Fs preferentially interact with pRB over other pocket protein family members.
E2F1 differs from the other activator E2Fs because of its ability to induce apoptosis (Johnson and Degregori, 2006) . The apoptotic potential of E2F1 appears to be necessary for the proper elimination of mouse thymocytes during T-cell development (Field et al., 1996) and for apoptosis in response to DNA damaging agents (Urist et al., 2004) . E2F1 promotes apoptosis by p53-dependent and p53-independent mechanisms, the latter involving transcriptional activation of p73 among other mechanisms (Ginsberg, 2002) . DNA damaging agents have been shown to activate apoptotic programs through phosphorylation and acetylation of E2F1 (Stevens and La Thangue, 2003) . Other studies have shown that E2F1 localizes to the promoter regions of pro-apoptotic and DNA damage response genes (Muller et al., 2001; Ren et al., 2002) . This background offers insight into the manner by which E2F1 exerts its distinct, pro-apoptotic activity.
We have previously shown that pRB contains two types of E2F binding sites, a 'general' site used by all E2Fs, and an E2F1 'specific' site in the pRB C terminus (Dick and Dyson, 2003) . These two pRB-E2F interactions are likely distinct because they rely on separate regions of E2F transcription factors for stable interaction with pRB. Recent crystallographic work has provided a detailed molecular model of the interaction between E2F1 and a fragment of the pRB C-domain (Rubin et al., 2005) . Based on dissociation constants they suggest that other E2Fs can make analogous interactions with pRB. This structural data questions whether E2F1 and pRB have a unique interaction mechanism.
Loss of the 'general' pRB-E2F interaction leaves pRB's ability to regulate E2F1-induced apoptosis intact, but abrogates the majority of its activity in cell cycle control (Dick and Dyson, 2003) . In this report, we demonstrate that pRB contains an E2F1-'specific' binding domain within a small portion of its C terminus. Furthermore, pRB interacts with a portion of E2F1 that is not found in other E2Fs. Using functional assays, we show that pRB's E2F1-'specific' binding domain can regulate E2F1-induced apoptosis, but contributes little function toward cell cycle control. This is significant because the 'general' E2F binding site remains fully capable of interacting with E2F1 when the 'specific' site is mutated. This indicates that E2F-induced cell cycle entry and apoptosis may not be regulated just by the timing of pRB-E2F interactions, but also by the physical nature of these interactions.
Results
Localization of the E2F1 interaction site within the pRB C terminus Our approach to characterizing the function of the E2F1-'specific' binding site ( Figure 1a ) was to map its location and disrupt it with point mutations. This was accomplished using the glutathione-S-transferase (GST)-retinoblastoma (RB) C-terminal fusion proteins (GST-RBC) listed in Supplementary Table 1. These proteins were used in pull-down assays to test their ability to bind to E2F1-DP1 complexes. These experiments defined amino acids 825 and 860 as the boundaries for an E2F1 binding module in pRB (Figure 1b ). This binding domain fits between the last cyclin/cdk phosphorylation site (T826) and the RxL motifs, nuclear localization signals, and part of the 'general' E2F binding site that lies beyond amino acid 860 ( Figure 1c ). We generated point mutations within this region and determined that substitution of M851A and V852A (mutant 77) disrupted E2F1-DP1 binding to the pRB C terminus (Figure 1d) .
A unique region of E2F1 contacts the 'specific' binding site in pRB Rubin et al. (2005) have recently reported a crystal structure of the pRB C terminus in complex with small fragments of E2F1 and DP1. Figure 2a shows a sequence alignment of amino acids from E2Fs 1 to 6 in the region where E2F1 forms contacts with the C terminus of pRB. Arrows mark amino acids in E2F1 that directly contact pRB. From this analysis, we noticed that many of these critical amino acids are not conserved between E2F1 and the other E2Fs. E2F3 and E2F1 have the same number of amino acids in this region of the sequence alignment, indicating that a comparison between them is ideal for determining if this part of E2F1 is essential in forming the 'specific' interaction with pRB. For this comparison, we generated chimeric E2F1 and E2F3 molecules where amino acids 272-282 of E2F1 are placed in the analogous region of E2F3 (325-335) and vice versa (Figure 2b ). Figure 2c shows that E2F1 can readily bind to the C terminus of pRB in GST binding assays, while E2F3's affinity for this piece of pRB is considerably lower because only a small portion of the 'general' site is present in the C terminus of pRB. As a control for integrity of our chimeric proteins, all E2F protein species are capable of binding to GST-RBLP. The chimeric 'E2F1 into 3' protein demonstrates that the 272-282 peptide from E2F1 can confer 'specific' binding activity when embedded in E2F3. Conversely, the reciprocal 'E2F3 into 1' protein is unable to bind to the pRB C terminus. This work reveals that the 'specific' pRB-E2F1 interaction is mediated by a primary amino acid sequence element that is unique to E2F1.
Selective effects of the M851A and V852A mutations on E2F1 binding RB proteins containing the M851A, V852A substitutions have been titled pRBDE2FS ('RBDS' or 'DS') since the mutation present in this protein selectively removes the E2F1-'specific' binding site. A pRBDE2FG þ DE2FS ('RBDGDS' or 'DGDS') has also been created and it contains the previously reported pRBDE2FG and the new pRBDE2FS mutations in the same molecule (Table 1 ). In pull-down assays, the analysis of GST-RBLP/E2F1-'specific' binding is confounded by the fact that the large pocket mediates both E2F-'general' and E2F1-'specific' binding interactions; thus, a loss of E2F1 binding is only seen in the compound mutant pRB-DGDS or when the C terminus of E2F1 is removed to block the 'general' interaction (Supplementary Figure 1) . These experiments demonstrate that the DS mutation in the pRB C terminus distinctly disrupts E2F1 interactions and leaves E2F2 and E2F3 binding intact. Anti-HA antibodies were used to immunoprecipitate HA-E2F-HA-DP1 complexes and RB proteins were detected by western blotting. Figures 3a-c demonstrate that the E2F binding characteristics of the pRB-DS and pRB-DGDS proteins seen in the GST pull-down assays with RBLP fragments are recapitulated with the full-length RB proteins. That is, E2F1 is deficient in binding to pRB-DGDS only, while E2F2-DP1 and E2F3-DP1 complexes demonstrate a selective ability to bind to the pRB-DS mutant. Figure 3d investigates the integrity of the 'LXCXE' binding cleft, a region of pRB that contacts viral oncoproteins such as SV40 Large T Antigen (TAg) but does not contribute to E2F interactions. As expected, TAg displays no significant defect in binding to pRB-DG, DS or DGDS proteins, as compared to WT pRB. This result shows that the secondary structure of these proteins is not significantly altered by the introduced mutations.
Taken together, the above experiments indicate that our mutant pRB molecules are ideal for probing the functional purpose of the different types of E2F interactions. In repeated transfections like these, the mutant constructs reliably express equivalent levels of protein. In addition, the binding defect in pRB-DS discretely affects only one type of E2F1 interaction.
pRB-DS retains regulation of E2F-dependent transcription Using these pRB mutants, we have investigated the importance of the 'specific' pRB-E2F1 interaction in transcriptional regulation of E2F-dependent reporters. As a comparison, we measured the ability of wild type and mutant RB proteins to block E2F1-, 2-or 3-mediated transactivation using an E2F responsive Figure 2 E2F1 contains a unique domain to mediate the 'specific' interaction with retinoblastoma protein (pRB). (a) A sequence alignment of E2F1-6 is shown to highlight similarities and differences in E2Fs at the 10 amino acid contact point with pRB. Arrows indicate amino acids identified in the crystal structure to directly mediate E2F1 and pRB contacts. (b) The relative position of the sequence that is exchanged between E2F1 and E2F3 is indicated. (c) Glutathione-S-transferase (GST) binding assays using the indicated HA-E2F and HA-DP complexes were evaluated by western blotting. The input level of GST proteins is shown in a Coomassie-stained gel. Abbreviations: CMV, cyto-megalovirus; GST, glutathione-S-transferase; RB, retinoblastoma. Amino acid substitutions made in GST-RBLP or full-length CMV-RB expression vectors are shown.
Specific E2F1 regulation by pRB LM Julian et al reporter plasmid, E2F4B-Luc. In these assays, wild-type pRB was expressed at the minimum level necessary for maximal repression of all three activator E2Fs (Figures  4a-c) . Under these conditions, pRB-DG was unable to regulate E2F transcription while pRB-DS was almost as effective as wild type in controlling E2F transcriptional activity. As expected, the DGDS mutant protein was also functionless. We next tested the ability of our pRB mutants to mediate E2F-dependent transcriptional repression. We co-transfected pRB expression plasmids, along with a p107-Luc reporter, into Saos-2 cells and determined luciferase activity. As seen in Figure 4d , wild-type pRB and pRB-DS repressed the promoter activity similarly. Likewise, pRB-DS has no obvious defect in blocking E2F1 activation of either the p107 or cyclin E1 promoters (Figures 4e and f) , two genes that are targets of endogenous E2F1 and pRB (Takahashi et al., 2000; Wells et al., 2000) . These experiments have provided the opportunity to compare the role of the 'general' and 'specific' E2F binding sites and to determine their relative contribution to transcriptional control through E2F1. This analysis shows that pRB-DS displays a reciprocal effect when compared with pRB-DG in terms of transcriptional regulation of E2F1 at cell cycle controlled promoters.
Cell cycle and apoptotic regulation by the pRB-E2F1 'specific' interaction To investigate the role of the 'specific' E2F1 binding site in cell cycle control we analysed the ability of our pRB constructs to induce a G 1 arrest when transfected at the lowest level capable of restoring activity. Representative DNA content histograms are shown in Figure 5a and the average G 1 content from three experiments is also displayed (Figure 5b ). Our analysis of the pRB-DS mutant revealed that it has no effect on cell cycle control by pRB. In comparison, the pRB-DG mutant showed a partial loss of cell cycle control and the pRB-DGDS mutant was almost functionless. This suggests that regulation of E2F1 through the 'specific' interaction only affects cell cycle control in the absence of the 'general' interaction.
E2F1 has been highlighted as a unique member of the E2F family because of its ability to induce an apoptotic cell death (Ginsberg, 2002) . To investigate the ability of our pRB mutants to regulate E2F1-induced apoptosis in proliferating cells, we co-transfected C33A cells with E2F1, DP1 and pRB plasmids, and used flow cytometry to quantitate cells containing a sub-G 1 DNA content. This assay is ideal because pRB has no effect on proliferative control in C33A cells, allowing us to study apoptosis in isolation (Strobeck et al., 2000) . Figure 6 illustrates that E2F1-DP1 expression induced apoptosis in C33A cells and, at the modest levels of expression resulting from these transfections, wild-type pRB could partially suppress this cell death. The DS mutation significantly abrogates this apoptotic regulation when compared to wild-type pRB (t-test, Po0.05). The pRB-DG mutant displayed an enhanced activity in this apoptotic inhibition assay as compared to wild type; however, pRB-DGDS lost all activity compared to pRB-DG (t-test, Po0.05). These results indicate that the integrity of the E2F1-'specific' binding domain within pRB is essential for regulating apoptosis in this assay. In addition, this experiment suggests that the surprising enhancement of apoptotic inhibitory activity of the pRB-DG mutant is due to the 'specific' binding site because its activity is completely lost in the DGDS combination.
In contrast to the cell cycle arrest and transcriptional reporter assays, we have demonstrated an apoptotic Specific E2F1 regulation by pRB LM Julian et al regulatory scenario where the 'specific' site on pRB has a clear role in blocking apoptotic induction. These experiments suggest an intriguing division of function between pRB's two E2F interaction sites.
Discussion
In this report, we have described the generation and characterization of an E2F1-'specific' pRB-binding mutant. In our previous work, we demonstrated that pRB contains two separate E2F binding sites and one is unique to E2F1 (Dick and Dyson, 2003) . We have now determined that the E2F1-'specific' binding interaction is largely dependent on a 35 amino acid region within the pRB C terminus and a 10 amino acid region in E2F1. Using mutations in pRB that discretely remove each E2F binding site, we have been able to rationally dissect pRB function. Our work shows that the E2F1-'specific' site is mostly responsible for E2F1-dependent apoptotic regulation, even though the E2F-'general' site in this mutant is capable of binding to E2F1. This suggests that pRB divides regulatory functions between two E2F interaction types (Figure 7a ). Current literature treats protein-protein interactions as sufficient for a positive or negative regulatory event. To our knowledge, this is the first example of different interaction configurations leading to separate functional consequences. This concept is further emphasized in the pRB-DG mutant by a gain in one function (apoptotic regulation) when the other is compromised (Figure 6 ). This novel regulatory concept is one of the highlights of this study.
Recently, the crystal structure of the human pRB C terminus bound to an E2F1-DP1 heterodimer has been reported (Rubin et al., 2005) . They demonstrate that M851 and V852 contact the E2F1-DP1 interface. Our data shows that these amino acids are involved in the 'specific' binding site on pRB and that the contact site on E2F1 is absent from other E2Fs. Based on this reasoning, we suggest that the crystal structure they have produced is a representation of the pRB-E2F1-'specific' interaction. 
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Sequence alignments of pRB molecules found in divergent vertebrate organisms demonstrate that the E2F1-'specific' binding domain stands out as a wellconserved feature of the pRB C terminus (Figure 7b ). The amino acids described in the crystal structure that make direct contacts with E2F1 or DP1 show nearly invariant conservation among pRB orthologues. In contrast, the C termini from other pocket proteins appear to lack the E2F1 'specific' binding domain altogether (Figure 7c ). Since pocket proteins, regardless of the host organism, can interact with E2Fs and contain the LXCXE binding cleft for interacting with chromatin regulators, we propose that the E2F1 'specific' binding site is a rare structural feature of pRB that distinguishes it from its other family members.
It is not clear how one type of interaction between pRB and E2F1 can inhibit apoptosis while a different interaction between these same molecules seems incapable of apoptotic control. One possibility is that pRB uses each E2F interaction type to regulate a distinct transcriptional program. Since the C33A cells used in our assays are deficient for p53 activity, 'specific' E2F1 regulation may be most relevant for p73-dependent death. For this reason, we tested pRB and E2F1 regulation of the p73 promoter. However, we were unable to detect regulatory activity that is different from what is shown for other E2F targets in Figure 4 (data not shown). Thus, it is not clear if p73 is a key downstream target of the 'specific' regulatory mechanism. It is also possible that transient reporter assays are not sophisticated enough to guide our analysis of this aspect of pRB regulation.
In summary, this report offers insight into a novel regulatory paradigm used by pRB to control E2F1. The conservation of the 'specific' binding domain in the C terminus of pRB argues that this is a fundamental aspect of the pRB's function. It will be exciting in the future to elucidate the biochemical mechanisms that allow the different configurations of E2F binding to mediate distinct functions.
Materials and methods

Plasmid constructions
Site-directed mutagenesis of the pRB C terminus, the large pocket domain, and E2Fs were carried out by PCR as previously described (Dick et al., 2000; Dick and Dyson, 2002) . As with previous mutagenesis, mutants generated in this study were selected for further study based on binding properties and uniformity of expression in repeated transfections (Dick et al., 2000; Dick and Dyson, 2002) . CMV-HA-E2F1, -E2F2 and -E2F3, p107(À280)-Luc, CMV-b-Gal, CMV-CD20, pBB14, pE2F4B-Luc, CMV-TAg and CMV-HA-DP1 plasmids and their sources have been described previously (Dick and Dyson, 2003) . cyclin E-Luc was a generous gift of Marie Classon (MGH, Boston, MA, USA).
Cell culture RB deficient Saos-2 and C33A cells were obtained from ATCC and cultured according to standard methods (Dick et al., 2000) . C33A cells were transfected to study protein-protein interactions and apoptosis. Saos-2 cells were used in transcription and cell cycle arrest experiments.
Protein binding assays GST pull-down and co-immunoprecipitation assays were performed as previously described (Dick et al., 2000) . E2F1 Figure 7 Origins and mechanism of differential regulation of E2F activity by retinoblastoma protein (pRB). (a) The 'general' interaction is able to potently regulate transcription of E2F responsive cell cycle promoters and arrest cell cycle progression in G 1 . The 'specific' interaction between pRB and E2F1 is required for the regulation of E2F1-induced apoptosis, but is dispensable for cell cycle control. Using these two types of E2F regulatory interactions, pRB can separately control distinct cellular events. (b) The E2F1 'specific' interaction domain is shaded in gray and arrows indicate the amino acids that have been shown to contact E2F1 in the crystal structure. (c) A similar analysis between pRB and other pocket proteins. Stars represent invariant conservation of amino acid identity, two dots represent conservative changes and single dots indicate semi-conserved substitutions.
was detected by monoclonal antibody KH95, E2F1 (1-374) by KH20, DP1 by WTH24, pRB by C36, SV40-TAg by PAb419 and HA-tagged E2Fs by 12CA5. Immunoprecipitations were performed with 12CA5 (HA) and PAb419 (TAg).
Luciferase reporter assays
Transcriptional reporter assays were carried out as reported previously (Dick et al., 2000) . Cells were harvested with Luciferase Assay Buffer (Promega, Madison, WI, USA) 36 h after transfection; the luciferase activity of each transfection was determined and normalized to b-Gal activity. The average of three independent transfections is shown and error bars indicate one standard deviation from the mean.
Flow cytometry assays Cell cycle Saos-2 cells were transfected and harvested as previously published (Dick et al., 2000) . Cells were stained with fluorescein anti-CD20 antibody and propidium iodide (PI) prior to flow cytometric analysis. The percentage of cells in each phase of the cell cycle was determined using Multicycle Software v3.0 (Phoenix Flow Systems, San Diego, CA, USA).
Apoptosis E2F1-dependent apoptosis was measured in transfected C33A cells as reported (Dick and Dyson, 2003) . Adherent and floating cells were harvested and stained with PI prior to analysis by flow cytometry for DNA content and green fluorescent protein (GFP) (to identify transfected cells). All graphs display the average of three independent transfections and error bars represent one standard deviation. Student's t-test was used to evaluate statistical confidence between selected means.
